OSIVAX - OXIVAX - AOI #28: INFLUENZA VACCINE INNOVATION. ADVANCING METAGENOMIC NEXT-GENERATION SEQUENCING BASED AGNOSTIC DIAGNOSTICS FOR VIRAL PATHOGENS THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO PREPARE THE IND PACKAGE FOR OVX836+SQ ADJUVANT.

On Feb 2, 2026, Department of Health and Human Services obligated $743,969.31 to OSIVAX for oxivax - aoi #28: influenza vaccine innovation. advancing metagenomic next-generation sequencing based agnostic diagnostics for viral pathogens the overall objective of this contract is to prepare the…. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. The contract is scheduled through Mar 31, 2027 — approximately 9 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.